196 related articles for article (PubMed ID: 34006286)
1. SCUBE3 serves as an independent poor prognostic factor in breast cancer.
Huo Q; He X; Li Z; Yang F; He S; Shao L; Hu Y; Chen S; Xie N
Cancer Cell Int; 2021 May; 21(1):268. PubMed ID: 34006286
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of HMGB3 and its prognostic value in breast cancer.
Zhou X; Zhang Q; Liang G; Liang X; Luo B
Front Oncol; 2022; 12():1048921. PubMed ID: 36620553
[TBL] [Abstract][Full Text] [Related]
3. SCUBE3 overexpression predicts poor prognosis in non-small cell lung cancer.
Zhao C; qin Q; Wang Q; Zhang J; Xu Y; Li W; Gu M; Chen S; Deng A
Biosci Trends; 2013 Dec; 7(6):264-9. PubMed ID: 24390364
[TBL] [Abstract][Full Text] [Related]
4. SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer.
Huo Q; Li Z; Cheng L; Yang F; Xie N
Front Oncol; 2020; 10():621. PubMed ID: 32528869
[No Abstract] [Full Text] [Related]
5. Activation of TGF-β1 Pathway by SCUBE3 Regulates TWIST1 Expression and Promotes Breast Cancer Progression.
Yang X; Hu J; Shi C; Dai J
Cancer Biother Radiopharm; 2020 Mar; 35(2):120-128. PubMed ID: 31742430
[No Abstract] [Full Text] [Related]
6. Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.
Sicking I; Rommens K; Battista MJ; Böhm D; Gebhard S; Lebrecht A; Cotarelo C; Hoffmann G; Hengstler JG; Schmidt M
BMC Cancer; 2014 Dec; 14():952. PubMed ID: 25511800
[TBL] [Abstract][Full Text] [Related]
7.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
8. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of
Lyu L; Wang M; Zheng Y; Tian T; Deng Y; Xu P; Lin S; Yang S; Zhou L; Hao Q; Wu Y; Dai Z; Kang H
Cancer Manag Res; 2020; 12():12457-12471. PubMed ID: 33299353
[TBL] [Abstract][Full Text] [Related]
10. SCUBE3 is an endogenous TGF-β receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer.
Wu YY; Peck K; Chang YL; Pan SH; Cheng YF; Lin JC; Yang RB; Hong TM; Yang PC
Oncogene; 2011 Aug; 30(34):3682-93. PubMed ID: 21441952
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
12. VWCE as a potential biomarker associated with immune infiltrates in breast cancer.
Huo Q; Li Z; Chen S; Wang J; Li J; Xie N
Cancer Cell Int; 2021 May; 21(1):272. PubMed ID: 34020650
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry.
Mattes MD; Bhatia JK; Metzger D; Ashamalla H; Katsoulakis E
J Breast Cancer; 2015 Jun; 18(2):143-8. PubMed ID: 26155290
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
16. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
17. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
18. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
19. Copper Chaperone for Superoxide Dismutase Subtypes as a Prognostic Marker in Luminal B Breast Cancer.
Li Y; Du W; Yang R; Wei X; Li H; Zhang X
Clin Med Insights Oncol; 2024; 18():11795549231219239. PubMed ID: 38187458
[TBL] [Abstract][Full Text] [Related]
20. CLIP4 Shows Putative Tumor Suppressor Characteristics in Breast Cancer: An Integrated Analysis.
Fan Y; He L; Wang Y; Fu S; Han Y; Fan J; Wen Q
Front Mol Biosci; 2020; 7():616190. PubMed ID: 33575272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
